Vanguard Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $1.26B | Sell |
|
|||||
|
2024
Q4 | $812M | Buy |
|
|||||
|
2024
Q3 | $704M | Buy |
|
|||||
|
2024
Q2 | $658M | Buy |
|
|||||
|
2024
Q1 | $638M | Buy |
|
|||||
|
2023
Q4 | $651M | Buy |
|
|||||
|
2023
Q3 | $445M | Buy |
|
|||||
|
2023
Q2 | $538M | Buy |
|
|||||
|
2023
Q1 | $457M | Buy |
|
|||||
|
2022
Q4 | $440M | Buy |
|
|||||
|
2022
Q3 | $378M | Buy |
|
|||||
|
2022
Q2 | $461M | Buy |
|
|||||
|
2022
Q1 | $477M | Buy |
|
|||||
|
2021
Q4 | $360M | Sell |
|
|||||
|
2021
Q3 | $257M | Buy |
|
|||||
|
2021
Q2 | $279M | Buy |
|
|||||
|
2021
Q1 | $228M | Buy |
|
|||||
|
2020
Q4 | $206M | Buy |
|
|||||
|
2020
Q3 | $160M | Buy |
|
|||||
|
2020
Q2 | $135M | Buy |
|
|||||
|
2020
Q1 | $80.8M | Buy |
|
|||||
|
2019
Q4 | $145M | Buy |
|
|||||
|
2019
Q3 | $31.2M | Sell |
|
|||||
|
2019
Q2 | $54.4M | Sell |
|
|||||
|
2019
Q1 | $51.4M | Buy |
|
|||||
|
2018
Q4 | $44.8M | Sell |
|
|||||
|
2018
Q3 | $85.6M | Buy |
|
|||||
|
2018
Q2 | $68.5M | Buy |
|
|||||
|
2018
Q1 | $78.7M | Buy |
|
|||||
|
2017
Q4 | $54M | Buy |
|
|||||
|
2017
Q3 | $54.7M | Buy |
|
|||||
|
2017
Q2 | $33.8M | Sell |
|
|||||
|
2017
Q1 | $44.6M | Buy |
|
|||||
|
2016
Q4 | $38.6M | Buy |
|
|||||
|
2016
Q3 | $37.5M | Buy |
|
|||||
|
2016
Q2 | $91.4M | Buy |
|
|||||
|
2016
Q1 | $43.8M | Buy |
|
|||||
|
2015
Q4 | $75.3M | Buy |
|
|||||
|
2015
Q3 | $38.5M | Buy |
|
|||||
|
2015
Q2 | $23.1M | Buy |
|
|||||
|
2015
Q1 | $15M | Buy |
|
|||||
|
2014
Q4 | $7.92M | Buy |
|
|||||
|
2014
Q3 | $5.55M | Buy |
|
|||||
|
2014
Q2 | $6.66M | Buy |
|
|||||
|
2014
Q1 | $6.14M | Buy |
|